With CancerIQ, we’re really going to be helping push population health into the oncology arena where we can hopefully predict and preempt this very costly and devastating disease well in advance, says Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
With CancerIQ, we’re really going to be helping push population health into the oncology arena where we can hopefully predict and preempt this very costly and devastating disease well in advance, says Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Transcript
How important is prevention through genetic testing for value-based care?
In a value-based care system, CancerIQ really is the model for that happening. In the realm of oncology in particular there are varying cancer types and we know it’s so expensive to treat once it becomes past a certain stage. CancerIQ really is on the forefront of detecting those early-onset aggressive cancers that tend to be hereditary and really trying to catch those early or reduce risk altogether. Another thing that’s unique about our company is that we really do work well with all types of providers from the oncologist who is identifying a hereditary cancer and needs it to drive the appropriate, most cost-effective treatment decision, to the [obstetrician/gynecologist] provider, who is really on the front lines making sure that patient’s going in for the right preventive service at the right time. With CancerIQ, we’re really going to be helping push population health into the oncology arena where we can hopefully predict and preempt this very costly and devastating disease well in advance.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More